Measuring proteins has great applicability in understanding the biology of health and disease, target discovery, target validation, preclinical development, translation, clinical development, companion diagnostics, and diagnostics.
SomaLogic has developed a transformative proteomic biomarker discovery technology that measures over 1129 human proteins (and growing) in small sample volumes (50 µL) with a sensitive, specific and semi-automated assay. To date we have assayed more than 20,000 samples, mostly clinical in nature, including a wide range of therapeutic areas. Matrices that have been run on our assay include serum, plasma, cells (both lysates and media), tissues, CSF, synovial fluid, and BAL.
SomaLogic is now offering academia, pharma and biotech companies access to this platform. This webinar will provide a brief overview of the technology and some example applications derived from it. We welcome you to join us to learn about this revolution in proteomics.
Steve Williams, M.D., Ph.D., Chief Medical Officer, SomaLogic
Steve Williams joined SomaLogic in 2009 as chief medical officer. Steve trained as a physician at Charing Cross and Westminster medical school, University of London, and following his internships, returned to the same institution for a Ph.D. in medicine and physiology. He subsequently performed three years of residency in diagnostic imaging at the University of Newcastle upon Tyne. He joined Pfizer in the U.K. in 1989 in experimental medicine, and worked on a variety of programs including asthma, irritable bowel syndrome, migraine [eletriptan], depression [sertraline] and urinary incontinence [darifenacin]. He moved to the U.S. in 1993 with Pfizer and worked in inflammatory bowel disease, stroke, psychosis [ziprasidone] and head injury. He created the clinical technology group in 1997, which became a worldwide function on five research sites with the objective of validating clinical biomarkers and measurements, and was made vice president in 2006. In process initiatives, he led or co-led initiatives in diagnostics, biomarkers, quality of drug candidates, and guidelines for development teams to make the decision to start Phase III trials.
Nick Saccomano, Ph.D., Chief Technology Officer, SomaLogic
Nick Saccomano joined SomaLogic in 2009. Nick obtained his Ph.D. in chemistry from Columbia University in 1984 under the direction of Professor Gilbert Stork. In 1984, he joined Pfizer Inc. as a research scientist in the CNS discovery group. Between 1985 and 1998, he held several positions in this group, including head of medicinal chemistry. During this time, Nick worked on or led many programs targeting psychiatric and neurological indications including depression, anxiety, psychosis, sleep, stroke, Parkinson’s disease, and Alzheimer’s disease. In 1998, he was promoted to vice president of discovery technology. In this role, Nick managed and developed a diverse set of enabling technologies used broadly across the drug discovery process within Pfizer. In 2004, Nick was promoted to senior vice president of global research technology and strategic alliances. In 2008, he moved to Bend Research Inc. as chief scientific officer, and he remains a member of the Board of Directors of this organization.
Who Should Attend?
Academia, Pharma and Biotechnology companies, particularly senior level executives involved in
- Biomarker discovery
- Preclinical development
- Clinical development
- Translation medicine
- Companion Diagnostics
SomaLogic, Inc., is a privately held biomarker discovery and clinical diagnostics company based in Boulder, Colorado. The company’s mission is to use its proprietary proteomic technology to develop enhanced protein analysis tools and reagents for the life sciences community, to facilitate biomarker discovery and validation for diagnostic and therapeutic applications, and to develop and commercialize clinical diagnostic products that will improve the delivery of healthcare by offering timely and accurate diagnostic information to physicians and their patients.